| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.8 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.0061 | 0.8 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.8 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | 0.0065 | 0.8 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.8 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.8 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.0069 | 0.8 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |